Feed RXRX
RX

Recursion Pharmaceuticals

RXRX · NASDAQ

$3.89 +6.58% (+$0.24)
1M +11.46%
Market Cap $2.04B
P/E Ratio -
Div. Yield -
ROE 50.41%
Piotroski F-Score Weak
3/9
Valuation
41 /100
Fair
P/S 37.21x
P/B 2.23x
P/E N/A
Growth
100 /100
Growing
Rev. growth 23.46%
Book val. growth 32.53%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 46.66%
FCF margin 645.82%
Net margin 945.92%
Quality
1 /100
Poor
ROIC 48.34%
Asset turnover 0.05x
ROE 50.41%
Debt
69 /100
Low
Debt/Equity 0.07x
Int. coverage -350.41x
Current ratio 5.03x
Stability
75 /100
Stable
Beta 1.07x
Profitable years 0
Rev. volatility 12.06%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre RXRX
Online

Despre companie

Recursion Pharmaceuticals is a biotechnology company that utilizes modern technologies such as artificial intelligence and machine learning to discover new therapeutic compounds and potential treatment approaches.

The key element of their approach is the use of image processing and data analysis systems to create comprehensive maps of cellular processes. This aims to identify potential targets for drugs and therapeutic substances in the fields of genetics, cellular biology, and diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Najat Khan

Employees

600

Headquarters

Salt Lake City

Evenimente viitoare

04 NOV.

Earnings

Upcoming earnings report

40d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.